Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17–48. https://doi.org/10.3322/caac.21763.

Article  PubMed  Google Scholar 

Ali NA, Hamdy NM, Gibriel AA, El Mesallamy HO. Investigation of the relationship between CTLA4 and the tumor suppressor RASSF1A and the possible mediating role of STAT4 in a cohort of Egyptian patients infected with hepatitis C virus with and without hepatocellular carcinoma. Arch Virol. 2021;166(6):1643–51. https://doi.org/10.1007/s00705-021-04981-8.

Article  CAS  PubMed  Google Scholar 

Youssef SS, Hamdy NM. SOCS1 and pattern recognition receptors: TLR9 and RIG-I; novel haplotype associations in Egyptian fibrotic/cirrhotic patients with HCV genotype 4. Arch Virol. 2017;162(11):3347–54. https://doi.org/10.1007/s00705-017-3498-7.

Article  CAS  PubMed  Google Scholar 

Zheng R, Zhang S, Zeng H, Wang S, Sun K, Chen R, Li L, Wei W, He J. Cancer incidence and mortality in China, 2016. J Natl Cancer Cent. 2022;2(1):1–9. https://doi.org/10.1016/j.jncc.2022.02.002.

Article  PubMed  PubMed Central  Google Scholar 

Donne R, Lujambio A. The liver cancer immune microenvironment: therapeutic implications for hepatocellular carcinoma. Hepatology. 2023;77(5):1773–96. https://doi.org/10.1002/hep.32740.

Article  PubMed  Google Scholar 

Bukowski K, Kciuk M, Kontek R. Mechanisms of multidrug resistance in cancer chemotherapy. Int J Mol Sci. 2020;21(9):3233. https://doi.org/10.3390/ijms21093233.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Colagrande S, Inghilesi AL, Aburas S, Taliani GG, Nardi C, Marra F. Challenges of advanced hepatocellular carcinoma. World J Gastroenterol. 2016;22(34):7645–59. https://doi.org/10.3748/wjg.v22.i34.7645.

Article  PubMed  PubMed Central  Google Scholar 

Hammad R, Eldosoky MA, Elmadbouly AA, Aglan RB, AbdelHamid SG, Zaky S, Ali E, Abd El Hakam FE, Mosaad AM, Abdelmageed NA, Kotb FM, Kotb HG, Hady AA, Abo-Elkheir OI, Kujumdshiev S, Sack U, Lambert C, Hamdy NM. Monocytes subsets altered distribution and dysregulated plasma hsa-miR-21–5p and hsa-miR-155–5p in HCV-linked liver cirrhosis progression to hepatocellular carcinoma. J Cancer Res Clin Oncol. 2023;149(17):15349–64. https://doi.org/10.1007/s00432-023-05313-w.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Czabotar PE, Lessene G, Strasser A, Adams JM. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol. 2014;15(1):49–63. https://doi.org/10.1038/nrm3722.

Article  CAS  PubMed  Google Scholar 

Sieghart W, Losert D, Strommer S, Cejka D, Schmid K, Rasoul-Rockenschaub S, Bodingbauer M, Crevenna R, Monia BP, Peck-Radosavljevic M, Wacheck V. Mcl-1 overexpression in hepatocellular carcinoma: a potential target for antisense therapy. J Hepatol. 2006;44(1):151–7. https://doi.org/10.1016/j.jhep.2005.09.010.

Article  CAS  PubMed  Google Scholar 

Chen L, Fletcher S. Mcl-1 inhibitors: a patent review. Expert Opin Ther Pat. 2017;27(2):163–78. https://doi.org/10.1080/13543776.2017.1249848.

Article  CAS  PubMed  Google Scholar 

Troiani M, Colucci M, D’Ambrosio M, Guccini I, Pasquini E, Varesi A, Valdata A, Mosole S, Revandkar A, Attanasio G, Rinaldi A, Rinaldi A, Bolis M, Cippa P, Alimonti A. Single-cell transcriptomics identifies Mcl-1 as a target for senolytic therapy in cancer. Nat Commun. 2022;13(1):2177. https://doi.org/10.1038/s41467-022-29824-1.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lu Y, Wu S, Yue Y, He S, Li J, Tang J, Wang W, Zhou HB. Gossypol with hydrophobic linear esters exhibits enhanced antitumor activity as an inhibitor of antiapoptotic proteins. ACS Med Chem Lett. 2016;7(12):1185–90. https://doi.org/10.1021/acsmedchemlett.6b00302.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tang G, Ding K, Nikolovska-Coleska Z, Yang CY, Qiu S, Shangary S, Wang R, Guo J, Gao W, Meagher J, Stuckey J, Krajewski K, Jiang S, Roller PP, Wang S. Structure-based design of flavonoid compounds as a new class of small-molecule inhibitors of the anti-apoptotic Bcl-2 proteins. J Med Chem. 2007;50(14):3163–6. https://doi.org/10.1021/jm070383c.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang H, Guo M, Wei H, Chen Y. Targeting MCL-1 in cancer: current status and perspectives. J Hematol Oncol. 2021;14(1):67. https://doi.org/10.1186/s13045-021-01079-1.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, Dayton BD, Ding H, Enschede SH, Fairbrother WJ, Huang DC, Hymowitz SG, Jin S, Khaw SL, Kovar PJ, Lam LT, Lee J, Maecker HL, Marsh KC, Mason KD, Mitten MJ, Nimmer PM, Oleksijew A, Park CH, Park CM, Phillips DC, Roberts AW, Sampath D, Seymour JF, Smith ML, Sullivan GM, Tahir SK, Tse C, Wendt MD, Xiao Y, Xue JC, Zhang H, Humerickhouse RA, Rosenberg SH, Elmore SW. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19(2):202–8. https://doi.org/10.1038/nm.3048.

Article  CAS  PubMed  Google Scholar 

Deeks ED. Venetoclax: first global approval. Drugs. 2016;76(9):979–87. https://doi.org/10.1007/s40265-016-0596-x.

Article  CAS  PubMed  Google Scholar 

Zhou Y, Li K, Li F, Han S, Wang Y, Li X. Doxorubicin and ABT-199 coencapsulated nanocarriers for targeted delivery and synergistic treatment against hepatocellular carcinoma. J Nanomater. 2019;1:5274598. https://doi.org/10.1155/2019/5274598.

Article  CAS  Google Scholar 

Chen L, Jiang X, Gao S, Liu X, Gao Y, Kow ASF, Tham CL, Lee MT. Sensitization effect of kaempferol from persimmon leaves on HepG2 hepatoma cells with ABT-199 resistance and its molecular mechanisms. Front Pharmacol. 2022;13:1032069. https://doi.org/10.3389/fphar.2022.1032069.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schwickart M, Huang X, Lill JR, Liu J, Ferrando R, French DM, Maecker H, O’Rourke K, Bazan F, Eastham-Anderson J, Yue P, Dornan D, Huang DC, Dixit VM. Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival. Nature. 2010;463(7277):103–7. https://doi.org/10.1038/nature08646.

Article  CAS  PubMed  Google Scholar 

Zhang HP, Li GQ, Zhang Y, Guo WZ, Zhang JK, Li J, Lv JF, Zhang SJ. Upregulation of Mcl-1 inhibits JQ1-triggered anticancer activity in hepatocellular carcinoma cells. Biochem Biophys Res Commun. 2018;495(4):2456–61. https://doi.org/10.1016/j.bbrc.2017.12.153.

Article  CAS  PubMed  Google Scholar 

Atta H, Alzahaby N, Hamdy NM, Emam SH, Sonousi A, Ziko L. New trends in synthetic drugs and natural products targeting 20S proteasomes in cancers. Bioorg Chem. 2023;133:106427. https://doi.org/10.1016/j.bioorg.2023.106427.

Article  CAS  PubMed  Google Scholar 

Anwar MM, Albanese C, Hamdy NM, Sultan AS. Rise of the natural red pigment “prodigiosin” as an immunomodulator in cancer. Cancer Cell Int. 2022;22(1):419. https://doi.org/10.1186/s12935-022-02815-4.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li Q, Tong Y, Chen J, Xie T. Targeting programmed cell death via active ingredients from natural plants: a promising approach to cancer therapy. Front Pharmacol. 2024;15:1491802. https://doi.org/10.3389/fphar.2024.1491802.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kubczak M, Szustka A, Rogalińska M. Molecular targets of natural compounds with anti-cancer properties. Int J Mol Sci. 2021;22(24):13659. https://doi.org/10.3390/ijms222413659.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hossain A, Shahidi F. Persimmon leaves: nutritional, pharmaceutical, and industrial potential-a review. Plants (Basel). 2023;12(4):937. https://doi.org/10.3390/plants12040937.

Article